Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 4:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,117 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: RheumatoId Arthritis Clear all
Terminated Phase 2 Interventional Results available

Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies

NCT00805467
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib Disodium (R935788)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
35
States / cities
La Jolla, California • Palm Desert, California • Palo Alto, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging

NCT03938636
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tc 99m tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 1Phase 2 Interventional

Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects

NCT00126724
View directory record Official record
Conditions
Arthritis, Rheumatoid, Arthritis, Psoriatic, Ankylosing Spondylitis
Interventions
tgAAC94 gene therapy vector, tgAAC94 placebo
Genetic
Lead sponsor
Targeted Genetics Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
22
States / cities
Glendale, Arizona • Tuscon, Arizona • Palm Desert, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2009 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis

NCT00550043
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
INCB018424, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Huntsville, Alabama • Upland, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 16, 2026, 4:02 PM EDT
Completed No phase listed Observational

Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities

NCT01456416
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 1 Interventional

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

NCT01417052
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
50 mg LX3305 QD, 100 mg LX3305 QD, 150 mg LX3305 QD, 200 mg LX3305 QD, 250 mg LX3305 QD, 300 mg LX3305 QD, 400 mg LX3305 QD, 250 mg LX3305 BID, 500 mg LX3305 QD, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Not applicable Interventional

A Novel Mobile App & Population Management System to Manage Rheumatoid Arthritis Flares

NCT02822521
View directory record Official record
Conditions
Arthritis, Rheumatoid Arthritis
Interventions
Mobile Application, Population Management System
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Not applicable Interventional Results available

Persona TM Tibia Clinical Outcomes Study

NCT03589300
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Collagen Disorders and/or Avascular Necrosis of the Femoral Condyle, Post-traumatic Loss of Joint Configuration, Moderate Valgus, Varus, or Flexion Deformities
Interventions
Persona TM Tibia
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Torrance, California • Wheat Ridge, Colorado • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 16, 2026, 4:02 PM EDT
Terminated Phase 1 Interventional

A Study to Evaluate Camoteskimab in Participants With Still's Disease

NCT04752371
View directory record Official record
Conditions
Adult Onset Still's Disease
Interventions
Camoteskimab (CERC-007, AVTX-007, AEVI-007)
Drug
Lead sponsor
Apollo Therapeutics Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Gainesville, Florida • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 16, 2026, 4:02 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

NCT03265132
View directory record Official record
Conditions
Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
Interventions
anakinra, Placebo
Biological · Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Beverly Hills, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 16, 2026, 4:02 PM EDT
Terminated No phase listed Observational

Evaluation of Salivary Gland Dysfunction

NCT00001196
View directory record Official record
Conditions
Sjogren's Syndrome, Salivary Gland
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
12 Years and older
Enrollment
1,740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1984 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 16, 2026, 4:02 PM EDT
Terminated Phase 3 Interventional Results available

A Study in Participants With Rheumatoid Arthritis

NCT01202773
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399, Placebo Q4W, Placebo Q2W
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
110
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Sep 16, 2026, 4:02 PM EDT
Completed No phase listed Observational

Myocardial Inflammation in Rheumatoid Arthritis: A Descriptive Study

NCT03776682
View directory record Official record
Conditions
Myocardial Inflammation, Rheumatoid Arthritis, Coronary Artery Disease, Myocardial Strain
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2023 · Synced Sep 16, 2026, 4:02 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions

NCT03510442
View directory record Official record
Conditions
Still's Disease, Adult-Onset, Systemic Inflammation, Arthritis, Autoinflammatory Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
1 Day to 100 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2050
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

NCT01711359
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Baricitinib, Methotrexate, Baricitinib Placebo, MTX Placebo, Folic Acid
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
47
States / cities
Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Not applicable Interventional

Ultrasound Treatment for Rheumatoid Arthritis Study [ULTRA Study]

NCT05417854
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Splenic Ultrasound
Device
Lead sponsor
SecondWave Systems Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects

NCT02880670
View directory record Official record
Conditions
Arthritis
Interventions
BMS-986142
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Sep 16, 2026, 4:02 PM EDT
Terminated Phase 2 Interventional Results available

Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

NCT00083759
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
natalizumab, placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
10
States / cities
Birmingham, Alabama • Tucson, Arizona • Escondido, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Sep 16, 2026, 4:02 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route

NCT06126042
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Test Product, Reference product, Reference Medicinal Product
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 16, 2026, 4:02 PM EDT
Terminated Phase 1 Interventional

Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients

NCT01559103
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MEDI5117, MEDI5117 Placebo
Biological
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
20 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Sep 16, 2026, 4:02 PM EDT
Terminated Phase 2 Interventional

A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT01862224
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
JNJ-38518168, Placebo, Methotrexate
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Sep 16, 2026, 4:02 PM EDT
Terminated Phase 3 Interventional Results available

Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.

NCT01770379
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Secukinumab (AIN457), Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
25
States / cities
Peoria, Arizona • Santa Monica, California • Upland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Sep 16, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

NCT00095173
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years to 17 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
10
States / cities
Omaha, Nebraska • Livingston, New Jersey • New Hyde Park, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 16, 2026, 4:02 PM EDT
Recruiting No phase listed Observational

Exactech Shoulder Post Market Clinical Follow-up Study

NCT05603728
View directory record Official record
Conditions
Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy, Ankylosing Spondylitis, Post-traumatic Osteoarthritis, Rheumatoid Arthritis, Fracture, Infections
Interventions
Not listed
Lead sponsor
Exactech
Industry
Eligibility
21 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2031
U.S. locations
24
States / cities
Laguna Woods, California • Redwood City, California • Stockton, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 16, 2026, 4:02 PM EDT